304 related articles for article (PubMed ID: 27489053)
21. Concomitant use of calcium channel blockers with dual antiplatelet therapy and re-hospitalization for acute coronary syndrome.
Wang CY; Lin ZF; Lee CM; Tsai YW; Huang TY; Shen LJ; Hsiao FY
Pharmacoepidemiol Drug Saf; 2017 Mar; 26(3):229-238. PubMed ID: 28067454
[TBL] [Abstract][Full Text] [Related]
22. Medical Therapy Utilization and Long-Term Outcomes Following Percutaneous Coronary Intervention: Five-Year Results From the Veterans Affairs Clinical Assessment, Reporting, and Tracking System Program.
Xie JX; Gunzburger EC; Kaun L; Plomondon ME; Barón AE; Waldo SW; Virani SS; Maddox TM; Mavromatis K
Circ Cardiovasc Qual Outcomes; 2019 Nov; 12(11):e005455. PubMed ID: 31665896
[TBL] [Abstract][Full Text] [Related]
23. Tackling inequalities: are secondary prevention therapies for reducing post-infarction mortality used without disparities?
Buja A; Boemo DG; Furlan P; Bertoncello C; Casale P; Baldovin T; Marcolongo A; Baldo V
Eur J Prev Cardiol; 2014 Feb; 21(2):222-30. PubMed ID: 22997352
[TBL] [Abstract][Full Text] [Related]
24. Comparative effectiveness of recommended versus less intensive drug combinations in secondary prevention of acute coronary syndrome.
Bezin J; Groenwold RH; Ali MS; Lassalle R; Robinson P; de Boer A; Moore N; Klungel OH; Pariente A
Pharmacoepidemiol Drug Saf; 2017 Mar; 26(3):285-293. PubMed ID: 28124399
[TBL] [Abstract][Full Text] [Related]
25. Target Doses of Secondary Prevention Medications Are Not Being Achieved in Patients With Reduced Left Ventricular Ejection Fraction After Acute Coronary Syndrome (ANZACS-QI 34).
Chan D; Doughty RN; Lund M; Lee M; Kerr AJ
Heart Lung Circ; 2020 Sep; 29(9):1386-1396. PubMed ID: 32423781
[TBL] [Abstract][Full Text] [Related]
26. Optimal pharmacological treatment and adherence to medication in secondary prevention of cardiovascular events in Spain: Results from the CAPS study.
Cordero A; Rodriguez Padial L; Batalla A; López Barreiro L; Torres Calvo F; Castellano JM; Ruiz E; Bertomeu-Martínez V;
Cardiovasc Ther; 2017 Apr; 35(2):. PubMed ID: 27957818
[TBL] [Abstract][Full Text] [Related]
27. Use of secondary prevention pharmacotherapy after first myocardial infarction in patients with diabetes mellitus.
Jørgensen CH; Gislason GH; Ahlehoff O; Andersson C; Torp-Pedersen C; Hansen PR
BMC Cardiovasc Disord; 2014 Jan; 14():4. PubMed ID: 24406095
[TBL] [Abstract][Full Text] [Related]
28. The UK National Health Service: delivering equitable treatment across the spectrum of coronary disease.
Hawkins NM; Scholes S; Bajekal M; Love H; O'Flaherty M; Raine R; Capewell S
Circ Cardiovasc Qual Outcomes; 2013 Mar; 6(2):208-16. PubMed ID: 23481523
[TBL] [Abstract][Full Text] [Related]
29. Patterns of treatment with antiplatelet therapy after an acute coronary syndrome: Data from a large database in a community setting.
Cimminiello C; Dondi L; Pedrini A; Ronconi G; Calabria S; Piccinni C; Polo Friz H; Martini N; Maggioni AP
Eur J Prev Cardiol; 2019 May; 26(8):836-846. PubMed ID: 30477319
[TBL] [Abstract][Full Text] [Related]
30. Treatment pattern of contemporary dual antiplatelet therapies after acute coronary syndrome: a Swedish nationwide population-based cohort study.
Angerås O; Hasvold P; Thuresson M; Deleskog A; ÖBraun O
Scand Cardiovasc J; 2016; 50(2):99-107. PubMed ID: 26564402
[TBL] [Abstract][Full Text] [Related]
31. Suboptimal achievement of low-density lipoprotein cholesterol targets in French patients with coronary heart disease. Contemporary data from the DYSIS II ACS/CHD study.
Ferrières J; Rouyer MV; Lautsch D; Ashton V; Ambegaonkar BM; Brudi P; Gitt AK;
Arch Cardiovasc Dis; 2017 Mar; 110(3):167-178. PubMed ID: 28209375
[TBL] [Abstract][Full Text] [Related]
32. Utilization of evidence-based therapy for the secondary prevention of acute coronary syndromes in Australian practice.
Vermeer NS; Bajorek BV
J Clin Pharm Ther; 2008 Dec; 33(6):591-601. PubMed ID: 19138236
[TBL] [Abstract][Full Text] [Related]
33. No gender differences in prognosis and preventive treatment in patients with AMI without significant stenoses.
Hansen KW; Hvelplund A; Abildstrøm SZ; Prescott E; Madsen M; Madsen JK; Jensen JS; Thuesen L; Thayssen P; Tilsted HH; Jørgensen E; Galatius S
Eur J Prev Cardiol; 2012 Aug; 19(4):746-54. PubMed ID: 21724682
[TBL] [Abstract][Full Text] [Related]
34. Optimal in-hospital and discharge medical therapy in acute coronary syndromes in Kerala: results from the Kerala acute coronary syndrome registry.
Huffman MD; Prabhakaran D; Abraham AK; Krishnan MN; Nambiar AC; Mohanan PP;
Circ Cardiovasc Qual Outcomes; 2013 Jul; 6(4):436-43. PubMed ID: 23800985
[TBL] [Abstract][Full Text] [Related]
35. Sex Differences in the Use of Statins in Community Practice.
Nanna MG; Wang TY; Xiang Q; Goldberg AC; Robinson JG; Roger VL; Virani SS; Wilson PWF; Louie MJ; Koren A; Li Z; Peterson ED; Navar AM
Circ Cardiovasc Qual Outcomes; 2019 Aug; 12(8):e005562. PubMed ID: 31416347
[TBL] [Abstract][Full Text] [Related]
36. Long-term secondary prevention of acute myocardial infarction (SEPAT) - guidelines adherence and outcome.
Ergatoudes C; Thunström E; Rosengren A; Björck L; Bengtsson Boström K; Falk K; Fu M
BMC Cardiovasc Disord; 2016 Nov; 16(1):226. PubMed ID: 27855640
[TBL] [Abstract][Full Text] [Related]
37. Secondary prevention of coronary artery disease in contemporary clinical practice.
Jankowski P; Czarnecka D; Wolfshaut-Wolak R; Łysek R; Łukaszewska A; Bogacki P; Grodecki J; Mirek-Bryniarska E; Nessler J; Podolec P; Kawecka-Jaszcz K; Pająk A
Cardiol J; 2015; 22(2):219-26. PubMed ID: 25299500
[TBL] [Abstract][Full Text] [Related]
38. Differences in the use of guideline-recommended therapies among 14 European countries in patients with acute coronary syndromes undergoing PCI.
Zeymer U; James S; Berkenboom G; Mohacsi A; Iñiguez A; Coufal Z; Sartral M; Paget MA; Norrbacka K; Ferrieres J; Bakhai A;
Eur J Prev Cardiol; 2013 Apr; 20(2):218-28. PubMed ID: 22345684
[TBL] [Abstract][Full Text] [Related]
39. Practice patterns and clinical outcomes among non-ST-segment elevation acute coronary syndrome (NSTE-ACS) patients presenting to primary and tertiary hospitals: insights from the EARLY glycoprotein IIb/IIIa inhibition in NSTE-ACS (EARLY-ACS) trial.
Toleva O; Westerhout CM; Senaratne MP; Bode C; Lindroos M; Sulimov VA; Montalescot G; Newby LK; Giugliano RP; Van de Werf F; Armstrong PW
Catheter Cardiovasc Interv; 2014 Nov; 84(6):934-42. PubMed ID: 24976083
[TBL] [Abstract][Full Text] [Related]
40. Systematic underutilisation of secondary preventive drugs in patients with acute coronary syndrome and reduced renal function.
Khedri M; Szummer K; Carrero JJ; Jernberg T; Evans M; Jacobson SH; Spaak J
Eur J Prev Cardiol; 2017 May; 24(7):724-734. PubMed ID: 28195517
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
